G1 Therapeutics is currently enrolling a multi-center, open-label study of the safety and efficacy of an investigational medicine plus or minus chemotherapy (Gemcitabine and Carboplatin) for patients with Triple Negative Breast Cancer (TNBC). 

To qualify for the study:

  • Patients must have locally recurrent or metastatic TNBC
  • Patients should not currently be receiving chemotherapy, however, prior treatment with chemotherapy is permitted  
  • Patients should be ready to start treatment